Aging · 2020 · 142 citations · 75 references
Life SciencesBiochemistryPharmacologyCancer PharmacologyDrug DiscoveryGlycobiologyCancer GlycobiologyCell-surface GlycansEnzyme InhibitionGlycan StructureGlycan-protein InteractionsGlycosylation PathwaysDimerization InhibitionInhibitor SpecificityN-linked Glycan StructurePd-l1 BlockadeProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 SignalingProtein Glycosylation Pathways
-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1. RSV was also predicted to interact with the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1. The ability of RSV to directly target PD-L1 interferes with its stability and trafficking, ultimately impeding its targeting to the cancer cell plasma membrane. Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte activity was notably exacerbated when cancer cells were previously exposed to RSV. This unforeseen immunomodulating mechanism of RSV might illuminate new approaches to restore T-cell function by targeting the PD-1/PD-L1 immunologic checkpoint with natural polyphenols.
75
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Jean‐Louis Chiasson, Robert G. Josse, Ramón Gomis et al. · The Lancet · 2002 · 2.5K citations
PLIP: fully automated protein–ligand interaction profiler
Sebastian Salentin, Sven B. Schreiber, V. Joachim Haupt et al. · Nucleic Acids Research · 2015 · 2.3K citations · Full text